Australia markets closed

BioPorto A/S (THOXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.75000.0000 (0.00%)
As of 09:36AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.7500
Open0.7500
BidN/A x N/A
AskN/A x N/A
Day's range0.7500 - 0.7500
52-week range0.6439 - 0.7500
Volume4,000
Avg. volume0
Market cap251.01M
Beta (5Y monthly)1.20
PE ratio (TTM)N/A
EPS (TTM)-0.0310
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Strong Performance of The NGAL Test Drives Revenue Growth

    May 11, 2022Announcement no. 11 Strong Performance of The NGAL Test Drives Revenue Growth Revenues totaled DKK 6.5 million in the first quarter of 2022, a 17% increase over the prior year. This growth was driven by a 70% increase in The NGAL Test sales, primarily from research use only (RUO) sales in the US and the timing of customer orders, which were up 116% over the prior year and a 10% increase in rest-of-the-world (ROW) sales of the test. ELISA kit revenue increased 138% in the first quarte

  • GlobeNewswire

    Grant of warrants

    May 5, 2022Announcement no. 10 Grant of warrants The Board of Directors of BioPorto A/S (“BioPorto”) (Nasdaq: BIOPOR), in accordance with its current authorization to issue warrants to key employees of BioPorto, today issued 270,000 warrants for the subscription of an equal number of shares. The warrants are issued in accordance with the company’s remuneration policy and the authorization in section 18 a of the Articles of Association. Each warrant grants the holder the right to subscribe for on

  • GlobeNewswire

    BioPorto A/S - Annual General Meeting

    April 28, 2022Announcement no. 9 BioPorto A/S - Annual General Meeting Today, BioPorto A/S held its Annual General Meeting. The general meeting resolved to conduct the meeting in English without simultaneous interpretation into Danish. Subsequently, the report on the Company’s activities was noted and the 2021 Annual Report was adopted, including the proposed allocation of the results. Discharge of liability was granted to the Board of Directors and the Executive Management, and the 2021 Remuner